Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$173.20M$173.20Mderived−8.5% vs Q4 2015 Net Income$15.30M$15.30Mderived−16.8% vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$22,300,000−37.5% Operating Cash Flowderived$38,500,000−24.5% Free Cash Flowderived$36,300,000−25.9% Margins · derivedOperating margin12.9%−6.0 pt vs Q4 2015
Net margin8.8%−0.9 pt vs Q4 2015
ended Jun 30, 2016 · filed Aug 10, 2016 · 41 d after period end